Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. China Regenerative Medicine International's selling, general, & admin. expense for the
six
months ended in Dec. 2025 was $3.18 Mil.
Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Dec. 2025 was $5.42 Mil.
China Regenerative Medicine International (OTCPK:CNRMF) Selling, General, & Admin. Expense Explanation
An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.
Warren Buffett likes companies with consistent SGA as the percentage of gross profit.
Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.
If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.
China Regenerative Medicine International Selling, General, & Admin. Expense Related Terms
China Regenerative Medicine International Selling, General, & Admin. Expense Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Regenerative Medicine International Selling, General, & Admin. Expense Chart
China Regenerative Medicine International Annual Data
CNRMF vs VRTX, REGN, RVMD: Selling, General, & Admin. Expense Comparison
For the Biotechnology subindustry, China Regenerative Medicine International's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Regenerative Medicine International Selling, General, & Admin. Expense vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, China Regenerative Medicine International's Selling, General, & Admin. Expense distribution charts can be found below:
* The bar in red indicates where China Regenerative Medicine International's Selling, General, & Admin. Expense falls into.
China Regenerative Medicine International Selling, General, & Admin. Expense Calculation
Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.
Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $5.42 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Selling, General, & Admin. Expense of $5.42 Mil mean?
China Regenerative Medicine International (CNRMF) has a Selling, General, & Admin. Expense of $5.42 Mil as of Dec. 2025. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on China Regenerative Medicine International and its competitors.
Is China Regenerative Medicine International's Selling, General, & Admin. Expense too high?
China Regenerative Medicine International's current Selling, General, & Admin. Expense is $5.42 Mil. Overall, China Regenerative Medicine International has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does China Regenerative Medicine International's Selling, General, & Admin. Expense compare to VRTX and REGN?
China Regenerative Medicine International's Selling, General, & Admin. Expense of $5.42 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Biotechnology company?
A good Selling, General, & Admin. Expense depends on the Biotechnology industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on China Regenerative Medicine International and its competitors. China Regenerative Medicine International's current Selling, General, & Admin. Expense is $5.42 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Regenerative Medicine International stock overvalued right now?
China Regenerative Medicine International (CNRMF) has a current Selling, General, & Admin. Expense of $5.42 Mil. The stock's GF Value™ is $0.09, compared to a current price of $0.04 — trading 61.1% below its estimated fair value. The current Selling, General, & Admin. Expense is $5.42 Mil. China Regenerative Medicine International's overall GF Score™ is 30/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For China Regenerative Medicine International (CNRMF), the current Selling, General, & Admin. Expense is $5.42 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Regenerative Medicine International (CNRMF) Overvalued in 2026?
Based on GuruFocus' analysis, China Regenerative Medicine International stock appears to be undervalued.
The current stock price of $0.04 is trading 61.1% below its estimated GF Value™ of $0.09.
Key valuation signals for CNRMF:
Selling, General, & Admin. Expense: $5.42 Mil
GF Value™: $0.09 vs. price of $0.04 (61.1% below fair value)
No single metric tells the full story. See the CNRMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Regenerative Medicine International Ltd is an investment holding company. The company is engaged in the provision of healthcare products and services. It is engaged in research and development, production and sales of tissue engineering and regenerative medicine products. The business scope of company includes tissue engineering, cosmetics, cell storage, preparation and therapy, hospitals administration and other business division. The segments of the company are Aesthetic medical and beauty services and Medical services. The majority of the company's revenue is derived from its Aesthetic medical and beauty services segment that provides medical beauty products and services. Geographically, the Hong Kong accounts for the majority of the revenue and also has a presence in PRC.
30GF Score
Get the complete analysis for CNRMF
Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CNRMF has been successfully added to your 
